Targeting GM-CSF for collagenase-induced osteoarthritis pain and disease in mice
KM-C Lee, V Prasad, A Achuthan, AJ Fleetwood, JA Hamilton, AD Cook
Osteoarthritis and Cartilage | ELSEVIER SCI LTD | Published : 2020
OBJECTIVES: Pharmacological options for treating osteoarthritis (OA) are limited and alternative treatments are required. Given the clinical data indicating that granulocyte macrophage-colony stimulating factor (GM-CSF) may be a therapeutic target in human OA, we evaluated different treatment regimens with a neutralizing anti-GM-CSF monoclonal antibody (mAb) in an experimental OA model to determine their effectiveness on amelioration of pain and disease. METHODS: The collagenase-induced osteoarthritis (CiOA) model was induced in C57BL/6 mice, followed by different treatment regimens of anti-GM-CSF mAb or isotype control. Anti-CCL17 mAb treatment was also administered continually during the l..View full abstract
Awarded by Arthritis Australia
This work was supported by grants from Arthritis Australia (1757679). A.D. Cook and J.A. Hamilton were supported by a grant (1085240), and J.A. Hamilton by a Senior Principal Research Fellowship from the National Health and Medical Research Council of Australia (NHMRC).